162 related articles for article (PubMed ID: 26559668)
1. Developmental DNA methyltransferase inhibitors in the treatment of gynecologic cancers.
Duenas-Gonzalez A; Medina-Franco JL; Chavez-Blanco A; Dominguez-Gomez G; Fernández-de Gortari E
Expert Opin Pharmacother; 2016; 17(3):323-38. PubMed ID: 26559668
[TBL] [Abstract][Full Text] [Related]
2. The Epigenetic Landscape in the Treatment of Gynecologic Malignancies.
Eskander RN
Am Soc Clin Oncol Educ Book; 2018 May; 38():480-487. PubMed ID: 30231335
[TBL] [Abstract][Full Text] [Related]
3. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review.
Husseinzadeh N; Husseinzadeh HD
Gynecol Oncol; 2014 May; 133(2):375-81. PubMed ID: 24556063
[TBL] [Abstract][Full Text] [Related]
4. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
Teixeira SR; Abreu CM; Parkes L; Davies J; Yao S; Sawhney MA; Margarit L; Gonzalez D; Pinto IM; Francis LW; Conlan RS
Biosens Bioelectron; 2019 Sep; 141():111386. PubMed ID: 31220725
[TBL] [Abstract][Full Text] [Related]
5. Rational study endpoints in anti-neoplastic agent regulatory approval trials in the gynecologic malignancies.
Markman M
Womens Health (Lond); 2016 Jul; 12(4):396-9. PubMed ID: 27638892
[TBL] [Abstract][Full Text] [Related]
6. DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies.
Fahy J; Jeltsch A; Arimondo PB
Expert Opin Ther Pat; 2012 Dec; 22(12):1427-42. PubMed ID: 23033952
[TBL] [Abstract][Full Text] [Related]
7. DNA hypermethylation as a chemotherapy target.
Ren J; Singh BN; Huang Q; Li Z; Gao Y; Mishra P; Hwa YL; Li J; Dowdy SC; Jiang SW
Cell Signal; 2011 Jul; 23(7):1082-93. PubMed ID: 21345368
[TBL] [Abstract][Full Text] [Related]
8. Metformin and gynecologic cancers.
Stine JE; Bae-Jump V
Obstet Gynecol Surv; 2014 Aug; 69(8):477-89. PubMed ID: 25144611
[TBL] [Abstract][Full Text] [Related]
9. Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.
Muggia FM
Semin Oncol; 2004 Dec; 31(6 Suppl 14):17-24. PubMed ID: 15726530
[TBL] [Abstract][Full Text] [Related]
10. Involvement of autophagy in cervical, endometrial and ovarian cancer.
Orfanelli T; Jeong JM; Doulaveris G; Holcomb K; Witkin SS
Int J Cancer; 2014 Aug; 135(3):519-28. PubMed ID: 24122662
[TBL] [Abstract][Full Text] [Related]
11. DNA methyltransferase inhibitors for cancer therapy.
Brueckner B; Kuck D; Lyko F
Cancer J; 2007; 13(1):17-22. PubMed ID: 17464242
[TBL] [Abstract][Full Text] [Related]
12. Targeting HER2 in ovarian and uterine cancers: challenges and future directions.
Teplinsky E; Muggia F
Gynecol Oncol; 2014 Nov; 135(2):364-70. PubMed ID: 25220628
[TBL] [Abstract][Full Text] [Related]
13. Clinical statistics of gynecologic cancers in Japan.
Yamagami W; Nagase S; Takahashi F; Ino K; Hachisuga T; Aoki D; Katabuchi H
J Gynecol Oncol; 2017 Mar; 28(2):e32. PubMed ID: 28198168
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for gynecologic cancers occurring during pregnancy.
Ko EM; Van Le L
Obstet Gynecol Surv; 2011 May; 66(5):291-8. PubMed ID: 21794193
[TBL] [Abstract][Full Text] [Related]
15. Myeloid-Derived Suppressor Cells as Therapeutic Targets in Uterine Cervical and Endometrial Cancers.
Mabuchi S; Sasano T
Cells; 2021 Apr; 10(5):. PubMed ID: 33946532
[TBL] [Abstract][Full Text] [Related]
16. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies.
Lyko F; Brown R
J Natl Cancer Inst; 2005 Oct; 97(20):1498-506. PubMed ID: 16234563
[TBL] [Abstract][Full Text] [Related]
17. Targeting DNA methylation for epigenetic therapy.
Yang X; Lay F; Han H; Jones PA
Trends Pharmacol Sci; 2010 Nov; 31(11):536-46. PubMed ID: 20846732
[TBL] [Abstract][Full Text] [Related]
18. Novel Therapies in Gynecologic Cancer.
Bejar FG; Oaknin A; Williamson C; Mayadev J; Peters PN; Secord AA; Wield AM; Coffman LG
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-17. PubMed ID: 35594502
[TBL] [Abstract][Full Text] [Related]
19. Incidence of cervical, endometrial, and ovarian cancer in Korea during 1999-2015.
Lim MC; Won YJ; Ko MJ; Kim M; Shim SH; Suh DH; Kim JW
J Gynecol Oncol; 2019 Jan; 30(1):e38. PubMed ID: 30574686
[TBL] [Abstract][Full Text] [Related]
20. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas.
Furlan D; Carnevali I; Marcomini B; Cerutti R; Dainese E; Capella C; Riva C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3329-36. PubMed ID: 16740754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
